Floatz logo

Innocell Autologous Cellular Immunotherapy

Recurrent Epithelial Ovarian Cancer Which Includes Epithelial Ovarian, Fallopian Tube and/or Primary Peritoneal Cancer

PhotonPharma, Inc.Cell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

244 Active assets in the Recurrent Epithelial Ovarian Cancer Which Includes Epithelial Ovarian, Fallopian Tube and/or Primary Peritoneal Cancer cohort.

Asset / SponsorPhaseRating
Trabectedin
AGO Research GmbH
Phase 4BBB
Mirvetuximab Soravtansine
AstraZeneca
Phase 3BBB
Irinotecan
OHSU Knight Cancer Institute
Phase 2BB
Olaparib
Imunon
Phase 4BB
Carboplatin
University of Washington
Phase 3BB

View all 50 →

Same molecule, other indications

Innocell Autologous Cellular Immunotherapy is also rated in:

ovarian cancerDormant
C
Indicative ·
36 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →